By Ethan Covey
A novel combination of bictegravir (BIC; Biktarvy, Gilead) and lenacapavir (LEN, Sunlenca, Gilead) appears highly effective in maintaining viral suppression over 48 weeks among virologically suppressed people with HIV who were switched from a complex antiretroviral therapy (ART), according to findings presented during the “ART nouveau” session at AIDS 2024 (abstract OAB2602).
The study participants reported that the combination of BIC, an integrase strand transfer